Enveric Biosciences enters $10M common stock purchase agreement with Lincoln Park Capital

Enveric Biosciences, Inc.

Lincoln Park commits to buy up to $10M of Enveric common stock over 24 months at the company's discretion.
Company issued 139,403 commitment shares as consideration for Lincoln Park's commitment.
Purchase price per share based on market prices; regular purchases up to 25,000 shares per day with potential increases.
Proceeds to be used for general corporate purposes including R&D, working capital, and possible acquisitions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Enveric Biosciences, Inc. entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at $10.0 million (effective 2023-11-03).

Action: entry
Agreement: equity purchase
Counterparty: Lincoln Park Capital Fund, LLC
Value: $10.0 million
Effective: 2023-11-03

Exact text from the filing

On November 3, 2023, Enveric Biosciences, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) and a registration rights agreement (the “Registration Rights Agreement”), with Lincoln Park Capital Fund, LLC (“Lincoln Park”), pursuant to which Lincoln Park has committed to purchase up to $10.0 million of the Company’s common stock

View on SEC.gov

38 material agreements filed in the last 30 days. Browse all material agreements →

Enveric Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-039443

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.